Compare Applovin Corporation (APP) vs Novavax Inc (NVAX) Price & Performance

AppLovin (APP) trades at $310.95, down 8.27% over 24 hours, reflecting recent bearish momentum after a Q2 2026 earnings miss. The stock shows strong profitability with a 64.58% net income margin and robust revenue growth of 53% YoY in Q2, but faces technical pressure with a bearish signal from moving averages. Recent news highlights a Bank of America downgrade to Neutral on August 11, 2026, citing uncertainty around sustaining 30% revenue growth, contributing to the stock's decline.

The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest upside, but execution risks and technical weakness pose near-term challenges. Investors should weigh high valuation multiples against growth sustainability concerns.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.